Literature DB >> 8610185

Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions.

P H Tu1, P Raju, K A Robinson, M E Gurney, J Q Trojanowski, V M Lee.   

Abstract

Mutations in the human Cu,Zn superoxide dismutase gene (SOD1) are found in 20% of kindreds with familial amyotrophic lateral sclerosis. Transgenic mice (line G1H) expressing a human SOD1 containing a mutation of Gly-93 --> Ala (G93A) develop a motor neuron disease similar to familial amyotrophic lateral sclerosis, but transgenic mice (line N1029) expressing a wild-type human SOD1 transgene do not. Because neurofilament (NF)-rich inclusions in spinal motor neurons are characteristic of amyotrophic lateral sclerosis, we asked whether mutant G1H and/or N1029 mice develop similar NF lesions. NF inclusions (i.e., spheroids, Lewy body-like inclusions) were first detected in spinal cord motor neurons of the G1H mice at 82 days of age about the time these mice first showed clinical evidence of disease. Other neuronal intermediate filament proteins (alpha-internexin, peripherin) also accumulated in these spheroids. The onset of accumulations of ubiquitin immunoreactivity in the G1H mice paralleled the emergence of vacuoles and NF-rich spheroids in neurons, but they did not colocalize exclusively with spheroids. In contrast, NF inclusions were not seen in the N1029 mice until they were 132 days old, and ubiquitin immunoreactivity was not increased in the N1029 mice even at 199 days of age. Astrocytosis in spinal cord was associated with a marked increase in glial fibrillary acidic protein immunoreactivity in the G1H mice, but not in the N1029 mice. Finally, comparative studies revealed a striking similarity between the cytoskeletal pathology in the G1H transgenic mice and in patients with amyotrophic lateral sclerosis. These findings link a specific SOD1 mutation with alterations in the neuronal cytoskeleton of patients with amyotrophic lateral sclerosis. Thus, neuronal cytoskeletal abnormalities may be implicated in the pathogenesis of human familial amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610185      PMCID: PMC39778          DOI: 10.1073/pnas.93.7.3155

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Electrophysiologic studies in the diagnosis and prognosis of motor neuron diseases.

Authors:  J R Daube
Journal:  Neurol Clin       Date:  1985-08       Impact factor: 3.806

2.  Interaction of the tail domain of high molecular weight subunits of neurofilaments with the COOH-terminal region of tubulin and its regulation by tau protein kinase II.

Authors:  H Miyasaka; S Okabe; K Ishiguro; T Uchida; N Hirokawa
Journal:  J Biol Chem       Date:  1993-10-25       Impact factor: 5.157

3.  Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis.

Authors:  F Côté; J F Collard; J P Julien
Journal:  Cell       Date:  1993-04-09       Impact factor: 41.582

4.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.

Authors:  H X Deng; A Hentati; J A Tainer; Z Iqbal; A Cayabyab; W Y Hung; E D Getzoff; P Hu; B Herzfeldt; R P Roos
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

5.  Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice.

Authors:  J L Cadet; P Sheng; S Ali; R Rothman; E Carlson; C Epstein
Journal:  J Neurochem       Date:  1994-01       Impact factor: 5.372

6.  SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis.

Authors:  G A Rouleau; A W Clark; K Rooke; A Pramatarova; A Krizus; O Suchowersky; J P Julien; D Figlewicz
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

7.  Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain.

Authors:  G Shaw; V Chau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease.

Authors:  T M Li; E Alberman; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

9.  Hippocampal mossy fiber changes in mice transgenic for the human copper-zinc superoxide dismutase gene.

Authors:  M Barkats; J Y Bertholet; P Venault; I Ceballos-Picot; A Nicole; J Phillips; R Moutier; P Roubertoux; P M Sinet; C Cohen-Salmon
Journal:  Neurosci Lett       Date:  1993-09-17       Impact factor: 3.046

10.  Assembly of type IV neuronal intermediate filaments in nonneuronal cells in the absence of preexisting cytoplasmic intermediate filaments.

Authors:  G Y Ching; R K Liem
Journal:  J Cell Biol       Date:  1993-09       Impact factor: 10.539

View more
  105 in total

1.  Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1.

Authors:  M D Nguyen; R C Larivière; J P Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease.

Authors:  B K Vanselow; B U Keller
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

Review 3.  Programmed cell death in amyotrophic lateral sclerosis.

Authors:  Christelle Guégan; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration.

Authors:  Y H Gong; A S Parsadanian; A Andreeva; W D Snider; J L Elliott
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

5.  Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.

Authors:  Hong Z Yin; Darryl T Tang; John H Weiss
Journal:  Exp Neurol       Date:  2007-07-24       Impact factor: 5.330

Review 6.  The wobbler mouse: a neurodegeneration jigsaw puzzle.

Authors:  Séverine Boillée; Marc Peschanski; Marie-Pierre Junier
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

7.  Modulation of mutant superoxide dismutase 1 aggregation by co-expression of wild-type enzyme.

Authors:  Mercedes Prudencio; Armando Durazo; Julian P Whitelegge; David R Borchelt
Journal:  J Neurochem       Date:  2008-12-11       Impact factor: 5.372

Review 8.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

9.  A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Authors:  Masataka Nakamura; Kevin F Bieniek; Wen-Lang Lin; Neill R Graff-Radford; Melissa E Murray; Monica Castanedes-Casey; Pamela Desaro; Matthew C Baker; Nicola J Rutherford; Janice Robertson; Rosa Rademakers; Dennis W Dickson; Kevin B Boylan
Journal:  Acta Neuropathol       Date:  2015-04-28       Impact factor: 17.088

Review 10.  Defective neurofilament transport in mouse models of amyotrophic lateral sclerosis: a review.

Authors:  Mala V Rao; Ralph A Nixon
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.